Physician profile
Patrick Tran
NPI 1689255697
$3,278.10
in general payments reported to CMS, 2019-2025
11 companies · $1,862 in 2025
The $1,862 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $512 · 2023: $416 · 2024: $488 · 2025: $1,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,926 · Travel and Lodging: $840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,926.36 |
| Travel and Lodging | $840.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,033.09 | 2025 | Accolade Sr |
| Amgen INC. | $588.12 | 2022-2025 | Otezla, Otezla |
| Genzyme Corporation | $404.27 | 2022-2025 | |
| Ucb, INC. | $369.90 | 2024-2025 | Bimzelx |
| Botanix Sb INC | $295.37 | 2025 | Sofdra |
| Pfizer INC. | $144.29 | 2022-2023 | |
| Biofrontera INC. | $125.00 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $113.12 | 2022 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Sun Pharmaceutical Industries INC. | $69.44 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $55.51 | 2023 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.